Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease

NCT02992132 is registered in ClinicalTrials.gov with ACADIA Pharmaceuticals Inc. as lead sponsor.

NCT NCT02992132
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02992132 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease
Lead sponsor
ACADIA Pharmaceuticals Inc.
Phase
Phase 2
Overall status
Terminated
Start date
November 30, 2016
Completion date
February 16, 2018
Enrollment
111 (actual)
Sites
56

Conditions

As the registry lists them; a condition with its own page is linked.

agitation and aggression in alzheimer's disease